Search results
Results from the WOW.Com Content Network
Revlimid: lenalidomide (in combination with dexamethasone) treatment of multiple myeloma patients who have received at least one prior therapy 06-29-2006
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone . [ 8 ]
The thalidomide molecule is a synthetic derivative of glutamic acid and consists of a glutarimide ring and a phthaloyl ring (Figure 5). [15] [16] Its IUPAC name is 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione and it has one chiral center [15] After thalidomide's selective inhibition of TNF-α had been reported, a renewed effort was put in thalidomide's clinical development.
The Ebers Papyrus – one of the most important medical papyri of ancient Egypt – was written around 1550 BCE, and covers more than 700 drugs, mainly of plant origin. [7] The first references to pills were found on papyri in ancient Egypt, and contained bread dough, honey, or grease.
Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.
BeiGene, Ltd. is a multinational oncology company. [3] It specializes in the development of drugs for cancer treatment. [4] Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has offices in North America, Europe, South America, Asia and Australia.
Celgene made Otezla available in the UK in 2015. [26] In 2019, Amgen acquired Otezla from Celgene for $13.4 billion. [27] [28] In 2020, Otezla generated $2.2 billion for Amgen. [29] Apremilast was listed on the PBS in Australia in January 2021, for chronic plaque psoriasis. [30]
Most importantly, zimelidine did not come with the adverse effect profile as the TCAs and therefore it became the template for the second generation SSRIs. [6] Zimelidine was the first SSRI to be marketed, but several cases of Guillain–Barré syndrome were associated with the use of the drug which led to withdrawal from the market in 1983 ...